Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Ovarian Cancer | Research article

LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression

Authors: Zhi-wei Qiao, Ying Jiang, Ling Wang, Lei Wang, Jing Jiang, Jing-ru Zhang, Peng Mu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Dysregulation of long non-coding RNAs (lncRNAs) has been identified in ovarian cancer. However, the expression and biological functions of LINC00852 in ovarian cancer are not understood.

Methods

The expressions of LINC00852, miR-140-3p and AGTR1 mRNA in ovarian cancer tissues and cells were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay. Gain- and loss-of-function assays were performed to explore the biological functions of LINC00852 and miR-140-3p in the progression of ovarian cancer in vitro. The bindings between LINC00852 and miR-140-3p were confirmed by luciferase reporter gene assay, RNA immunoprecipitation (RIP) assay and RNA pull-down assay.

Results

We found that LINC00852 expression was significantly up-regulated in ovarian cancer tissues and cells, whereas miR-140-3p expression was significantly down-regulated in ovarian cancer tissues. Functionally, LINC00852 knockdown inhibited the viability, proliferation and invasion of ovarian cancer cells, and promoted the apoptosis of ovarian cancer cells. Further investigation showed that LINC00852 interacted with miR-140-3p, and miR-140-3p overexpression suppressed the viability, proliferation and invasion of ovarian cancer cells. In addition, miR-140-3p interacted with AGTR1 and negatively regulated its level in ovarian cancer cells. Mechanistically, we found that LINC00852 acted as a ceRNA of miR-140-3p to promote AGTR1 expression and activate MEK/ERK/STAT3 pathway. Finally, LINC00852 knockdown inhibited the growth and invasion ovarian cancer in vivo.

Conclusion

LINC00852/miR-140-3p/AGTR1 is an important pathway to promote the proliferation and invasion of ovarian cancer.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Rottmann M, Burges A, Mahner S, Anthuber C, Beck T, Grab D, et al. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol. 2017;143(9):1833–44. https://doi.org/10.1007/s00432-017-2422-6.CrossRefPubMed

Doubeni CA, Doubeni AR, Myers AE. Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2016;93(11):937–44.PubMed

Li S, Lv M, Qiu S, Meng J, Liu W, Zuo J, et al. NF-κB p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin. J Cell Mol Med. 2019;23(6):4338–48. https://doi.org/10.1111/jcmm.14325.CrossRefPubMedPubMedCentral

Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA Cancer J Clin. 2017;67(6):493–506. https://doi.org/10.3322/caac.21408.CrossRefPubMed

Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28:viii61–5.CrossRefPubMed

Pignata S, Cecere SC, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28:viii51–6.CrossRefPubMed

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88. https://doi.org/10.1016/S0140-6736(13)62146-7.CrossRefPubMed

Liang H, Yu T, Han Y, Jiang H, Wang C, You T, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 2018;17(1):119. https://doi.org/10.1186/s12943-018-0870-5.CrossRefPubMedPubMedCentral

10.

Wu D-D, Chen X, Sun K-X, Wang L-L, Chen S, Zhao Y. Role of the lncRNA ABHD11-AS (1) in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer. 2017;16(1):138. https://doi.org/10.1186/s12943-017-0709-5.CrossRefPubMedPubMedCentral

11.

Liu P, Wang H, Liang Y, Hu A, Xing R, Jiang L, et al. LINC00852 promotes lung adenocarcinoma spinal metastasis by targeting S100A9. J Cancer. 2018;9(22):4139–49. https://doi.org/10.7150/jca.26897.CrossRefPubMedPubMedCentral

12.

Li Q, Wang X, Jiang N, Xie X, Liu N, Liu J, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma. Cancer Med. 2020;9(17):6354–66. https://doi.org/10.1002/cam4.3303.CrossRefPubMedPubMedCentral

13.

Jiang W, Li T, Wang J, Jiao R, Shi X, Huang X, et al. miR-140-3p suppresses cell growth and induces apoptosis in colorectal cancer by targeting PD-L1. OncoTargets Ther. 2019;12:10275–85. https://doi.org/10.2147/OTT.S226465.CrossRef

14.

Zhou Y, Wang B, Wang Y, Chen G, Lian Q, Wang H. miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28. Oncol Lett. 2019;17(4):3835–41. https://doi.org/10.3892/ol.2019.10038.CrossRefPubMedPubMedCentral

15.

Chen M-S, Lin C-H, Huang L-Y, Qiu X-M. CircRNA SMARCC1 sponges MiR-140-3p to regulate cell progression in colorectal cancer. Cancer Manag Res. 2020;12:4899–910. https://doi.org/10.2147/CMAR.S254185.CrossRefPubMedPubMedCentral

16.

Salem O, Erdem N, Jung J, Münstermann E, Wörner A, Wilhelm H, et al. The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics. 2016;17(1):566. https://doi.org/10.1186/s12864-016-2869-x.CrossRefPubMedPubMedCentral

17.

Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012;5(1):164. https://doi.org/10.1186/1756-0500-5-164.CrossRefPubMedPubMedCentral

18.

Cooper HA, Scalia R, Rizzo V, Eguchi S. Angiotensin II- and Alzheimer-type cardiovascular aging. Circ Res. 2018;123(6):651–3. https://doi.org/10.1161/CIRCRESAHA.118.313477.CrossRefPubMedPubMedCentral

19.

Yap RWK, Shidoji Y, Yap WS, Masaki M. Association and interaction effect of AGTR1 and AGTR2 gene polymorphisms with dietary pattern on metabolic risk factors of cardiovascular disease in Malaysian adults. Nutrients. 2017;9(8):853. https://doi.org/10.3390/nu9080853.CrossRefPubMedCentral

20.

Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer. 2005;92(7):1247–52. https://doi.org/10.1038/sj.bjc.6602483.CrossRefPubMedPubMedCentral

21.

Oh E, Kim JY, Cho Y, An H, Lee N, Jo H, et al. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial–mesenchymal transition and promotes tumor growth and angiogenesis. Biochim Biophys Acta (BBA) – Mol Cell Res. 2016;1863(6):1071–81. https://doi.org/10.1016/j.bbamcr.2016.03.010.CrossRef

22.

Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y, et al. Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep. 2012;27(3):783–90. https://doi.org/10.3892/or.2011.1554.CrossRefPubMed

23.

Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4(1):2516. https://doi.org/10.1038/ncomms3516.CrossRefPubMed

24.

Zhang Q, Yu S, Lam MMT, Poon TCW, Sun L, Jiao Y, et al. Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. J Exp Clin Cancer Res. 2019;38(1):116. https://doi.org/10.1186/s13046-019-1127-x.CrossRefPubMedPubMedCentral

25.

Xie J, Xu Y, Huang X, Chen Y, Fu J, Xi M, et al. Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway. Tumor Biol. 2015;36(2):1279–88. https://doi.org/10.1007/s13277-014-2754-7.CrossRef

26.

Milovic V, Teller IC, Murphy GM, Caspary WF, Stein J. Deoxycholic acid stimulates migration in colon cancer cells. Eur J Gastroenterol Hepatol. 2001;13(8):945–9. https://doi.org/10.1097/00042737-200108000-00012.CrossRefPubMed

27.

Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932–48. https://doi.org/10.7150/thno.25541.CrossRefPubMedPubMedCentral

28.

Liao D, Zhong L, Duan T, Zhang R-H, Wang X, Wang G, et al. Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-κB pathway. Clin Cancer Res. 2015;21(23):5349–59. https://doi.org/10.1158/1078-0432.CCR-15-0198.CrossRefPubMed

29.

Wu X-S, Wang F, Li H-F, Hu Y-P, Jiang L, Zhang F, et al. LncRNA-PAGBC acts as a microRNA sponge and promotes gallbladder tumorigenesis. EMBO Rep. 2017;18(10):1837–53. https://doi.org/10.15252/embr.201744147.CrossRefPubMedPubMedCentral

30.

Huang L, Zhou Y, Cao X-P, Lin J-X, Zhang L, Huang S-T, et al. KPNA2 promotes migration and invasion in epithelial ovarian cancer cells by inducing epithelial-mesenchymal transition via Akt/GSK-3β/Snail activation. J Cancer. 2018;9:157–65. https://doi.org/10.7150/jca.20879.CrossRefPubMedPubMedCentral

31.

Wu S, Donigan A, Platsoucas CD, Jung W, Soprano DR, Soprano KJ. All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1. Exp Cell Res. 1997;232(2):277–86. https://doi.org/10.1006/excr.1997.3495.CrossRefPubMed

32.

Liu J, Guo Q, Chen B, Yu Y, Lu H, Li Y-Y. Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90. FEBS Lett. 2006;580(1):245–50. https://doi.org/10.1016/j.febslet.2005.12.005.CrossRefPubMed

33.

Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, et al. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin Exp Metastasis. 2015;32(5):441–55. https://doi.org/10.1007/s10585-015-9718-1.CrossRefPubMed

34.

Wu X, Wu Y, Ye B, Wu F, Wang P. High expression of ghrelin and obestatin prepropeptide in tumor tissues predicted adverse overall survival in gastric carcinoma patients. Medicine. 2020;99(26):e20635. https://doi.org/10.1097/MD.0000000000020635.CrossRefPubMedPubMedCentral

35.

Seim I, Carter SL, Herington AC, Chopin LK. Complex organisation and structure of the ghrelin antisense strand gene GHRLOS, a candidate non-coding RNA gene. BMC Mol Biol. 2008;9(1):95. https://doi.org/10.1186/1471-2199-9-95.CrossRefPubMedPubMedCentral

36.

Wu W, Gao H, Li X, Zhu Y, Peng S, Yu J, et al. LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression. Cancer Sci. 2019;110(5):1587–98. https://doi.org/10.1111/cas.14009.CrossRefPubMedPubMedCentral

37.

Yan H, Li H, Li P, Li X, Lin J, Zhu L, et al. Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis. J Exp Clin Cancer Res. 2018;37(1):237. https://doi.org/10.1186/s13046-018-0910-4.CrossRefPubMedPubMedCentral

38.

Shang A, Wang W, Gu C, Chen C, Zeng B, Yang Y, et al. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J Exp Clin Cancer Res. 2019;38(1):411. https://doi.org/10.1186/s13046-019-1394-6.CrossRefPubMedPubMedCentral

39.

Wu S, Liu J, Wang X, Li M, Chen Z, Tang Y. Aberrant expression of the long non-coding RNA GHRLOS and its prognostic significance in patients with colorectal cancer. J Cancer. 2017;8(19):4040–7. https://doi.org/10.7150/jca.21304.CrossRefPubMedPubMedCentral

40.

Thomas PB, Seim I, Jeffery PL, Gahete MD, Maugham M, Crisp GJ, et al. The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth. Int J Oncol. 2019;55(6):1223–36. https://doi.org/10.3892/ijo.2019.4891.CrossRefPubMedPubMedCentral

41.

Liang S, Gong X, Zhang G, Huang G, Lu Y, Li Y. The lncRNA XIST interacts with miR-140/miR-124/iASPP axis to promote pancreatic carcinoma growth. Oncotarget. 2017;8(69):113701–18. https://doi.org/10.18632/oncotarget.22555.CrossRefPubMedPubMedCentral

42.

Hao T, Wang Z, Yang J, Zhang Y, Shang Y, Sun J. MALAT1 knockdown inhibits prostate cancer progression by regulating miR-140/BIRC6 axis. Biomed Pharmacother. 2020;123:109666. https://doi.org/10.1016/j.biopha.2019.109666.CrossRefPubMed

43.

Liu W, Liu P, Gao H, Wang X, Yan M. Long non-coding RNA PGM5-AS1 promotes epithelial-mesenchymal transition, invasion and metastasis of osteosarcoma cells by impairing miR-140-5p-mediated FBN1 inhibition. Mol Oncol. 2020;14(10):2660–77. https://doi.org/10.1002/1878-0261.12711.CrossRefPubMedPubMedCentral

44.

Li Y, Xu J, Guo YN, Yang BB. LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140. Eur Rev Med Pharmacol Sci. 2019;23(8):3401–9. https://doi.org/10.26355/eurrev_201904_17704.CrossRefPubMed

45.

Zhang Q-Y, Men C-J, Ding X-W. Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN. J Cell Biochem. 2019;120(9):14885–98. https://doi.org/10.1002/jcb.28750.CrossRefPubMed

46.

Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, et al. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 2014;355(1):46–53. https://doi.org/10.1016/j.canlet.2014.09.019.CrossRefPubMed

47.

Wang C-X, Xiong H-F, Wang S, Wang J, Nie X, Guo Q, et al. Overexpression of TEM8 promotes ovarian cancer progression via Rac1/Cdc42/JNK and MEK/ERK/STAT3 signaling pathways. Am J Transl Res. 2020;12(7):3557–76.PubMedPubMedCentral

48.

Zhang D, Liu H, Yang B, Hu J, Cheng Y. L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. Biosci Rep. 2019;39(5):BSR20190469. https://doi.org/10.1042/BSR20190469.CrossRefPubMedPubMedCentral

49.

Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018;9:2923.CrossRefPubMedPubMedCentral

50.

Guo L, Chen J, Liu D, Liu L. OIP5-AS1/miR-137/ZNF217 Axis promotes malignant behaviors in epithelial ovarian cancer. Cancer Manag Res. 2020;12:6707–17. https://doi.org/10.2147/CMAR.S237726.CrossRefPubMedPubMedCentral

51.

Ge J, Han T, Shan L, Na J, Li Y, Wang J. Long non-coding RNA THOR promotes ovarian Cancer cells progression via IL-6/STAT3 pathway. J Ovarian Res. 2020;13(1):72. https://doi.org/10.1186/s13048-020-00672-1.CrossRefPubMedPubMedCentral

Title: LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression
Authors: Zhi-wei Qiao
Ying Jiang
Ling Wang
Lei Wang
Jing Jiang
Jing-ru Zhang
Peng Mu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08730-7

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study

A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma

Multiple myeloma in Armenia during the period 2006–2018: facts and discussion

Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome

Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4–B1: a pilot study